ONO has signed a definitive merger agreement with Deciphera to enhance its oncology portfolio and expand its presence across the US & the EU, strengthening kinase drug discovery research
Under the agreement, ONO will acquire Deciphera’s outstanding shares for $25.60 per unit in cash followed by merging Deciphera with its subsidiary, totaling $2.4B in equity value. The transaction will conclude in Q3’24
The acquisition will further add Qinlock (switch-control inhibitor) to treat 4L gastrointestinal stromal tumor (approved in the US & 40 other regions), its drug candidates incl. vimseltinib & DCC-3116 (an ULK inhibitor) along with additional oncology candidates to ONO’s portfolio
Ref: Deciphera | Image: ONO Pharmaceutical
Related News:- Deciphera Presents Results of Qinlock (ripretinib) in P-III (INTRIGUE) Study for the Treatment of Gastrointestinal Stromal Tumor at ASCO 2022
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
